Summary
This paper presents a systematic methodology for prioritising drug repurposing candidates by integrating pharmacological data from DrugBank with genomic information and longitudinal clinical records from a large de-identified DNA repository (BioVU) at Vanderbilt University Medical Centre. The authors identified approximately 230 practical opportunities for genomic drug repurposing and developed a pipeline of 14 candidates across 7 disease areas. The approach demonstrates how target genomics can be combined with existing drug databases and clinical data to identify high-potential candidates for repurposing in randomised controlled trials.
UK applicability
The methodology is technology and database-agnostic and could be adapted to UK healthcare systems with equivalent electronic health record and genomic repositories, such as those within the NHS. However, direct application would require access to comparable large-scale linked genomic and clinical data systems in the United Kingdom.
Key measures
Target-action pairs; pharmacodynamic variables; marketing variables; genomic data quality control thresholds; disease areas; repurposing candidate pipeline
Outcomes reported
The study identified approximately 230 target-action pairs representing practical opportunities for genomic drug repurposing, and narrowed these to a pipeline of 14 repurposing candidates across 7 disease areas. The candidates were selected based on integration of pharmacodynamic and marketing variables with genomic quality control thresholds derived from electronic health record data.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.